Halozyme Therapeutics hired pharmaceutical veteran Benjamin Hickey as the company’s chief commercial officer, it was recently announced.

Hickey is charged with building and executing the company’s commercial strategy, including for PEGPH20, currently in trials for multiple cancers.

In the spring the company initiated final-stage trials for use of the drug in pancreatic cancer, known for being a death sentence since typically discovered in advanced stages.

In addition, Hickey will be responsible for building Halozyme's global oncology commercial organization, spanning sales, marketing and market access teams.

Hickey was previously with pharmaceutical giant Bristol-Myers Squibb, where he most recently was general manager, UK & Ireland.